Onkos Surgical receives FDA clearance to expand antibacterial implant technology

Onkos Surgical has received FDA 510(k) clearance to extend its NanoCept antibacterial technology to titanium implants within the ELEOS Limb Salvage System, broadening the use of its infection-resistant implant coating in complex orthopedic procedures.

The clearance represents the second 510(k) authorization following the original De Novo approval and builds on a prior clearance granted in October 2025 for the proximal tibia component.

NanoCept is designed to reduce bacterial contamination on implant surfaces, particularly in oncology and revision surgery patients, who face higher infection risks. Preclinical data cited by the company show activity against common pathogens including Staphylococcus aureus (MRSA and MSSA), E. coli, and Pseudomonas aeruginosa.

Chief Medical Officer Dr. Steven Gitelis said:

“Having NanoCept available on titanium is meaningful because it expands the antibacterial options we have in cases where every detail counts.”

CEO Patrick Treacy added:

“This clearance enables broader integration of our antibacterial technology into the implants surgeons already rely on for limb reconstruction.”

The expanded approval strengthens Onkos Surgical’s ELEOS platform and increases the availability of antibacterial-coated implants in limb salvage and complex orthopedic reconstruction procedures.